In silico investigation of phytoconstituents from Cameroonian medicinal plants towards COVID-19 treatment

Samir Chtita1 · Romuald Tematio Fouedjou2 · Salah Belaidi3 · Loris Alvine Djoumbissie4 · Mebarka Ouassaf3 · Faizan Abul Qais5 · Mohamed Bakhouch6,7 · Mohammed Efendi8 · Tugba Taskin Tok8,9 · Mohammed Bouachrine10,11 · Tahar Lakhlifi11

Received: 28 November 2021 / Accepted: 7 April 2022 / Published online: 29 April 2022
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022

Abstract
In silico studies performed on the metabolites of four Cameroonian medicinal plants with a view to propose potential molecules to fight against COVID-19 were carried out. At first, molecular docking was performed for a set of 84 selected phytochemicals with SARS-CoV-2 main protease (PDB ID: 6lu7) protein. It was further followed by assessing the pharmacokinetics and pharmacological abilities of 15 compounds, which showed low binding energy values. As the screening criteria for their ADMET properties were performed, only two compounds have shown suitable pharmacological properties for human administration which were shortlisted. Furthermore, the stability of binding of these compounds was assessed by performing molecular dynamics (MD) simulations. Based on further analysis through molecular dynamics simulations and reactivity studies, it was concluded that only the Pycnanthuquinone C (17) and the Pycnanthuquinone A (18) extracted from the *Pycnanthus angolensis* could be considered as candidate inhibitors for targeted protein. Indeed, we expect that these compounds could show excellent in vitro and in vivo activity against SARS-CoV-2.

Keywords SARS-CoV-2 · Cameroonian medicinal plants · Pycnanthuquinone · Pycnanthus angolensis · Molecular docking · Molecular dynamics · ADMET
Introduction

The respiratory system can be affected by illnesses ranging from acute infections such as pneumonia, bronchitis, influenza, and colds [1]; chronic conditions such as asthma and sinusitis; and chronic obstructive pulmonary disease or symptoms such as cough [2]. The control of these diseases in developing countries depends closely on traditional medicine and more specifically on herbal remedies made from local medicinal plants [3, 4]. With this, tremendous expansion in the use of traditional medicine, in particular, herbal medicines has led to a plethora of ethnobotanical investigations conducted. These, later, have proven to be one of the most reliable approaches for the discovery of new drugs [5]. Although the Cameroonian flora is rich in medicinal plant species, only a few ethnobotanical studies have been identified, some plants for their use to treat respiratory diseases [6]. However, respiratory diseases present a high cost for both patients and for society [1]. In addition, secondary metabolites have shown great and rapid action than generic drugs in the treatment of many microbial and viral infections. Moreover, secondary metabolites of some medicinal plant species have been isolated, purified, and characterized. It appears that these plants are rich with secondary metabolites, which are known for their potential biological activities [7, 8]. The Cameroonian flora could therefore be a source of interesting secondary metabolites that could be used to fight against emerging infection including the SARS-CoV-2 and its novel variants.

According to the World Health Organization, the worldwide situation update shows that from 31 December 2019 and as to the first week of October 2021, a total of 234 M cases (compare to 88.8 M cases in January) of COVID-19 have been reported worldwide, including 4.8 M deaths (compare 1.9 M death cases in January), which show an increase of infected case (145.2 M) and number of death (2.9 M) during 9 months. In Africa, the situation is also alarming with 6 M cases and 0.15 M deaths; the five countries reporting the most high number of cases are South Africa (2.9 M), Morocco (0.9 M), Tunisia (0.7 M), Ethiopia (0.35 M), and Egypt (0.31) [9]. These statistics demonstrate that developing countries are not preserved and are inundated by this viral infectious disease, which now occupies an important place in the global incidence of transmissible diseases. Several attempts to manage this pandemic, despite all the advances made in modern and orthodox medicine, have posed mankind a lot of health consequences. Traditional medicine has consequently gained renewed interest in health care services. In addition, it is estimated that at least 25% of all modern medicines are derived directly or indirectly from medicinal plants, mainly through the application of modern technologies to traditional knowledge [10].

As a part of our ongoing bioprospection for anti-COVID-19 agents, we observed significant antiviral activity of some secondary metabolites isolated from common medicinal plants of the Asteraceae family [11]. Things that prompted us to carry out an in silico study on secondary metabolites isolated from others medicinal plants, based on ethnobotanical survey made in some Cameroonian villages. The study aims to promote the use of traditional pharmacopeia in a possible treatment of COVID-19 infection. The secondary metabolites collected from the identified species were used to generate ligands, which will be used for docking studies towards main target protein of SARS-CoV-2.

Indeed, the interaction modes of 84 potential antiviral candidates were studied regarding the SARS-CoV-2 main protease (Mpro) protein using virtual screening, molecular docking, and molecular dynamics methods.

Materials and methods

Construction of phytochemical database

The dataset of this study was constructed by gathering 84 phytochemicals from plants belonging to Cameroonian flora commonly used to treat respiratory infections. This set was collected as follows: 28 from Pycnanthus angolensis (Myristicaceae) [12–16], 25 from Paullinia pinnata Linn (Sapindaceae) [17–26], 18 from Allanblackia monticola Staner L.C. (Guttiferae) [27–29], and 13 from Alchornea cordifolia (Euphorbiaceae) [30–33] (Table S1). The three-dimensional structures of these phytochemicals were obtained from the PubChem database.

In order to perform molecular docking analysis, the structures of the 84 phytochemicals were optimized and converted into a single database format (SDF) using Discovery Studio 2020 software. Molecular docking study was performed for each compound of the set with main protease (Mpro) SARS-CoV-2 protein.

Pharmacological and pharmacokinetic as well as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) proprieties of the studied compounds were also assessed by using SwissADME webserver (http://www.swissadme.ch) [34]. The SwissADME server was used to determine the ADME characteristics of the studied compounds and involving the assessment of the drug-like characteristics as well as their possible toxicity.

Ligand–protein targets virtual screening

Molecular docking is considered as one of the best computational methods used to highlight the bonding modes of molecules (ligands) with the targets [35–38], because of its
ability to predict the conformation and mode of binding of the ligand to the receptor binding site.

The three-dimensional structure of M\textsuperscript{pro} protein bounded with N3 inhibitor was downloaded from Protein Data Bank (PDB ID: 6lu7). Firstly, before performing the molecular docking, the two proteins are prepared. The N3 inhibitor, water molecules, and all non-protein elements were removed, and hydrogen atoms were added to the structure.

Next, the preparation of ligands that will be docked to proteins consists of adding hydrogen atoms to these ligands and optimizing their structure. The site of binding is defined as the volume occupied by the co-crystallized ligands in each of the receptors pocket.

The protein and ligands as well as the ligand entry site into the protein pockets are prepared in the present work by using Discovery Studio 2016 software. In addition, AutoDock software (ADT) MGLTools 1.5.6 packages are used in the re-docking of the co-ligands with the receptor and in the docking of molecules for the 84 molecules with M\textsuperscript{pro} SARS-CoV-2 protein.

The 3D grid box dimensions were (20 × 20 × 20) Angstrom, with coordinates of \(x = -10.641, y = 11.847, \) and \(z = 68.346\) to suit the binding site of removed N3 inhibitor.

According to the results of recent molecular mechanics studies, Nelfinavir antiviral drug has been chosen to serve as a reference ligand with SARS-CoV-2 M\textsuperscript{pro} (6lu7) protein in this study [39–43].

This work explores molecular docking in the identification of the most important active sites and in the analyzing of the interactions that occur between the docked molecules and the identified active site.

The obtained results were evaluated according to the binding energy value, and the molecule with the lowest binding energy (best score) was considered as the best one that interacts with the target.

**ADMET analysis of top drug candidates**

Drug candidates should match many criteria as a basic step of drug discovery process in order to be considered as orally consumed drugs. Physicochemical properties (molecular weight, H bonding, heavy atoms, etc.), drug likeness properties (Lipinski et al. rule [44], bioavailability), water solubility, pharmacokinetics, stability, and low cost of production are evaluated to make a point of view about adopting this drug or not. In the present study, SwissADME webserver was used to evaluate the ADMET properties of the top selected molecules.

**Determining the toxicity of potential drugs**

Examining the toxicological characteristics of the drug candidates and ensuring their safety are one of the most important stages to be followed to approve any novel drug. In this study, ProTox-II online web server (https://tox-new.charite.de/protox_II) was utilized to evaluate the toxicological properties of the selected molecules; this server predicts the values of oral toxicity, cytotoxicity, carcinogenicity, immunotoxicity, and mutagenicity. Some toxicity-related evaluations have also been added, such as minnow toxicity (MT), hepatotoxicity (HP), and skin sensitization (SS). All previous properties are fundamental for the access to toxicological risk.

**Molecular dynamics simulations**

Compounds that have showed highest binding affinity were selected for further studies using molecular dynamics (MD) simulation. The MD simulation was performed using Gromacs-2018.1 packages with amber99sb-ILDN force field [45, 46]. The topology of both ligands was prepared using Antechamber packages in AmberTools19 [47]. The stability of the protein–ligand complexes for Mpro protein was studied using MD simulation. The protein and their complexes were solvated using TIP3P water model in triclinic boxes separately. All structures were neutralized by adding sodium or chlorine counter ions. The steepest minimization of 5000 steps was performed to remove weak Van der Waals contacts. All systems were then equilibrated for NVT and NPT for 1 ns each. The NVT equilibration was done at 300 K using V-rescale thermostat and the NPT equilibration was performed at 1.0 bar using Parrinello-Rahman barostat [48, 49]. The 100-ns MD simulation was carried out and a total of 10,000 frames of each system were saved at 10 ps intervals. All trajectories were subjected to PBC corrections before analysis using standard Gromacs utilities. One hundred frames from the trajectory of each complex were extracted from 60 to 100 ns for the MM-PBSA calculations [50].

**Results and discussion**

**Molecular docking simulations**

Firstly, the co-crystallized ligand is re-docked into the active site to validate the accuracy of molecular docking. Based on the inhibitor N3 with 6lu7, the binding site was found to be mostly located in the hydrophobic cleft lined by the following amino acids: Glu166, Thr190, Gln189, Phe140, His41, His163, His164, His172, Gly143, Leu141, Leu167, Asn142, Met49, Met167, Met165, Pro168, and Ala191.

It can be seen from Fig. 1 that there are eight hydrogen bond interactions with eight different amino acids, two with Glu166 and six with Phe140, Gly143, His163, His164, Gln189, and Thr190. There are two C-H interactions with Met165 and His172, and three hydrophobic Pi-alkyl interactions with Pro168, Ala191, and His41. Further inquiry indicates the presence of an Amide-Pi stacked interaction with Leu141 [51].
Then, molecular docking was performed for the 84 ligands with the Mpro SARS-CoV-2 protein using AutoDock1.5.6 software. As it can be noticed from Table 1, molecules 40, 68, and 70 show the best binding affinity to the virus protein with binding energy of $-8.5$ kcal/mol.

![Fig. 1 Different interactions for the inhibitor binding of 6lu7 with N3](image)

**Table 1** The binding energies BE (kcal/mol) of the 84 studied ligands with the Mpro (PDB ID: 6lu7) SARS-CoV-2 protein using docking modeling

| N°  | BE  | N°  | BE  | N°  | BE  | N°  | BE  |
|-----|-----|-----|-----|-----|-----|-----|-----|
| 01  | −7.2| 22  | −6.9| 43  | −4.8| 64  | −7.2|
| 02  | −7.2| 23  | −6.8| 44  | −5.0| 65  | −7.3|
| 03  | −7.1| 24  | −7.0| 45  | −5.5| 66  | −7.8|
| 04  | −7.0| 25  | −7.2| 46  | −7.5| 67  | −6.2|
| 05  | −7.7| 26  | −7.0| 47  | −6.2| 68  | −8.5|
| 06  | −7.1| 27  | −7.7| 48  | −7.9| 69  | −7.4|
| 07  | −7.2| 28  | −7.3| 49  | −7.4| 70  | −8.5|
| 08  | −7.5| 29  | −7.9| 50  | −8.4| 71  | −7.3|
| 09  | −5.4| 30  | −7.7| 51  | −6.3| 72  | −6.9|
| 10  | −7.2| 31  | −5.0| 52  | −7.6| 73  | −4.5|
| 11  | −7.0| 32  | −7.7| 53  | −7.4| 74  | −7.5|
| 12  | −8.0| 33  | −6.5| 54  | −7.4| 75  | −7.4|
| 13  | −7.7| 34  | −7.0| 55  | −7.6| 76  | −7.5|
| 14  | −6.9| 35  | −7.6| 56  | −7.3| 77  | −5.1|
| 15  | −7.8| 36  | −7.9| 57  | −7.6| 78  | −5.1|
| 16  | −7.2| 37  | −7.9| 58  | −7.1| 79  | −5.5|
| 17  | −7.8| 38  | −6.5| 59  | −7.0| 80  | −5.9|
| 18  | −8.3| 39  | −7.4| 60  | −6.9| 81  | −5.6|
| 19  | −7.5| 40  | −8.5| 61  | −7.1| 82  | −7.5|
| 20  | −7.0| 41  | −8.3| 62  | −8.0| 83  | −6.8|
| 21  | −6.8| 42  | −4.8| 63  | −7.2| 84  | −5.8|
Table 2 2D structures and binding energy values (in kcal/mol) of the top 15 compounds

| Compound                                                                 | BE  | Compound                                                                 | BE  |
|---------------------------------------------------------------------------|-----|---------------------------------------------------------------------------|-----|
| Diosmetin-7-O-(2''-O-ß-D-apiofuranosyl-6''-acetyl-ß-D-glucopyranoside) (49) | -8.5| Morelloflavone (68)                                                      | -8.5|
| Volkensiflavone (70)                                                      | -8.3| 3-O-ß-D-glucopyranosyl(1→6)-ß-D-glucopyranosyleanolic acid (50)          | -8.4|
| Pycnanthuquinone B (18)                                                   | -8.3| Friedelín (41)                                                            | -8.3|
| Pycnanthulignene D (12)                                                   | -8.0| 2-(1-hydroxy-3,3-dimethylidihydroxylyl)-dihydro-6-deoxyjacareubin (62)   | -8.0|
| (3ß)-3-O-(2'-Acetamido-2'-deoxy-ß-D-glucopyranosyl) oleanolic acid (29)    | -7.9| 6ß-(3'-methoxy-4'-hydroxybenzoyl)-lup-20(29)-ene-3-one (56)               | -7.9|
| 6ß-(3'-methoxy-4'-hydroxybenzoyl)-lup-20(29)-ene-3-one (56)               | -7.9| Tricetin-4-O-methyl-7-O-(2''-O-ß-D-apiofuranosyl-6''-acetyl-ß-D-glucopyranoside) (48) | -7.9|
| Pycnanthuquinone A (15)                                                   | -7.8| Pycnanthuquinone C (17)                                                  | -7.8|
| Dihydro-6-deoxyjacareubin (66)                                           | -7.8|                                                                           |     |
Structural conformation analysis of the complexes (ligand–protein) was carried out to unpick the drug surface hotspot of the target. Molecular interaction types between protein and ligand were identified also; ligand-bounded amino acid residues were determined. Table 2 gather studied compounds showed had the best molecular docking scores with Mpro SARS-CoV-2 protein.

From the obtained outcomes of the molecular docking study, fifteen compounds have exhibited the best scores of binding energy values closely to the Nelfinavir (−8.2 kcal/mol). These results allowed us support to suggest the 15 studied compounds as promising SARS-CoV-2 inhibitors.

As depicted in Fig. 2C, Nelfinavir has shown the following interaction types with the Mpro protein of SARS-CoV-2: two H-bonds with Gly339 residue and four hydrophobic interactions with Phen374, Trp436, Leu335, and Val367 residues.

Although compound 18, obtained from Pycnanthus angolensis, was reported that it binds to 6lu7 protein with energy value of −8.3 kcal/mol; herein, it shows three H-bond interactions which maintain the stability of the complex. Two of them was formed with Gly143 amino acid residue and the third one with Ser144 amino acid residue of the Mpro protein, at respective distances of 2.96 Å, 3.27 Å, and 2.87 Å (Fig. 2B).

Compound 17, isolated from Pycnanthus angolensis, exhibits a binding energy of −7.8 kcal/mol with the SARS-CoV-2 Mpro protein. This compound interacts with the Mpro protein through H-bond with His41 amino acid residue at distance of 2.24 Å and pi-anion interaction with Glu166 residue at distance of 4.14 Å (Table 3). The interaction modes are illustrated in Fig. 2A.

We can conclude that the following amino acid residues His41, Glu166, and Ser144 of the Mpro protein contribute significantly in the stability of compounds 17 and 18.

**Drug-likeness and pharmacokinetic studies**

Drug candidates should possess favorable ADME properties and ideally non-toxic. Therefore, the designed compounds were evaluated of their ADME profile, including

**Table 3** Different interactions and key residues for the inhibitor binding between 6lu7 and compounds 17 and 18

| Amino acid | Distance (Å) | Interaction type | Type of HB interaction |
|------------|--------------|------------------|------------------------|
| 17         | HIS41        | 2.24             | H-Bond                 | Strong     |
|            | GLU166       | 4.14             | Pi-Anion               | ——         |
| 18         | GLY143       | 2.96             | H-Bond                 | Strong     |
|            | GLY143       | 3.27             | H-Bond                 | Average    |
|            | SER144       | 2.87             | H-Bond                 | Strong     |

2.5 Å < d < 3.10 Å = > strong interaction; 3.1 Å < d < 3.55 Å = > average interaction
Table 4  Molecular properties and ADME prediction of ligand compounds

| N  | MW g/mol | log P | HBA | HBD | N.rot | TPSA (Å²) | log S mol/l | Lipinski | Veber | Bioavailability score | PAINS alert | GI | BBB | Cyp1A2 | Cyp2C19 | Cyp2C9 | Cyp2D6 | Cyp3A4 | Log kp |
|----|----------|-------|-----|-----|-------|-----------|-------------|-----------|-------|----------------------|-------------|----|-----|-------|-------|-------|-------|-------|-------|
| 12 | 352.38   | 2.68  | 5   | 1   | 3     | 57.15     | −5.39       | Yes       | Yes   | 0.55                 | 0           | High| Yes | Yes   | Yes   | Yes   | No    | No    | No    | −4.95|
| 15 | 472.57   | 1.51  | 7   | 4   | 7     | 132.13    | −4.46       | Yes       | Yes   | 0.56                 | 1           | Low | No  | No    | No    | No    | Yes   | −6.75|
| 17 | 436.54   | 3.04  | 5   | 2   | 3     | 91.67     | −5.90       | Yes       | Yes   | 0.56                 | 1           | High| No  | No    | No    | Yes   | No    | Yes   | −5.11|
| 18 | 490.63   | 1.87  | 7   | 4   | 7     | 132.13    | −4.49       | Yes       | Yes   | 0.56                 | 0           | Low | No  | No    | No    | No    | Yes   | −6.96|
| 29 | 659.89   | 3.14  | 8   | 5   | 6     | 145.55    | −7.25       | Yes       | No    | 0.56                 | 0           | Low | No  | No    | No    | No    | Yes   | −6.14|
| 36 | 588.86   | 5.97  | 4   | 1   | 5     | 63.60     | −9.69       | No        | Yes   | 0.17                 | 0           | Low | No  | No    | No    | No    | No    | −2.65|
| 37 | 590.88   | 6.05  | 4   | 2   | 5     | 66.76     | −9.90       | No        | Yes   | 0.17                 | 0           | Low | No  | No    | No    | No    | No    | −2.44|
| 40 | 638.57   | −2.84 | 16  | 7   | 10    | 240.36    | −2.97       | No        | No    | 0.17                 | 0           | Low | No  | No    | No    | No    | No    | −10.61|
| 41 | 426.72   | 6.92  | 1   | 0   | 0     | 17.07     | −8.66       | Yes       | Yes   | 0.55                 | 0           | Low | No  | No    | No    | No    | No    | −1.94|
| 48 | 654.57   | −3.30 | 17  | 8   | 10    | 260.59    | −2.85       | No        | No    | 0.17                 | 0           | Low | No  | No    | No    | No    | No    | −10.95|
| 50 | 780.98   | 0.88  | 13  | 8   | 7     | 215.83    | −6.58       | No        | No    | 0.11                 | 0           | Low | No  | No    | No    | No    | No    | −8.40|
| 62 | 398.45   | 1.86  | 6   | 3   | 3     | 100.13    | −5.20       | Yes       | Yes   | 0.55                 | 0           | High| No  | No    | No    | Yes   | No    | −5.66|
| 66 | 312.32   | 1.29  | 5   | 2   | 0     | 79.90     | −3.79       | Yes       | Yes   | 0.55                 | 0           | High| No  | Yes   | No    | Yes   | Yes   | −6.44|
| 68 | 558.49   | 0.09  | 11  | 7   | 3     | 194.21    | −6.18       | No        | No    | 0.17                 | 1           | Low | No  | No    | Yes   | No    | Yes   | −6.72|
| 70 | 542.49   | 0.58  | 10  | 6   | 3     | 173.98    | −6.32       | No        | No    | 0.17                 | 0           | Low | No  | No    | Yes   | No    | Yes   | −6.38|
drug-likeness, partition coefficient, solubility, human intestinal absorption, penetration of the blood brain barrier (BBB), cytochrome P450 inhibition, and several other parameters using SwissADME. The results show among the 15 studied molecules, two molecules were capable to pass ADME profiling to the toxicity aspect study used ProTox-II webserver with reference of Globally Harmonized System (UN, 2013).

Drug-likeness is a key criterion in screening drug candidates at the earlier phase of drug discovery and development. This parameter can be described as a mean to correlate physicochemical aspect of a compound with its biopharmaceutical aspect in the human body, especially its influence in bioavailability of per oral route [52].

Two different rule-based filters, Lipinski et al. [44, 53], were used to calculate the drug and lead likeness for the 15 selected compounds. The results exhibited that the compounds 29, 36, 37, 40, 48, 50, 68, and 70 have violated the understudy drug-likeness rules (Lipinski’s criteria: less than 5 HBD, less than 10 HBA, a MW less than 500 g/mol and log P not greater than 5 and Veber’s criteria: TPSA should be less than 140 Å² and the NRB should be less than 10). These results suggest that these compounds have a low theoretical oral bioavailability according to the Lipinski’s rule-of-five and bioavailability score value.

Another important property of oral drugs is solubility in intestinal fluid, because insufficient solubility can limit intestinal absorption through the portal vein system. All of the compounds having low aqueous solubility level are shown in Table 4, except for compounds 12, 15, 17, 18, 40, 48, 62, and 66 that have shown moderate solubility. The aqueous solubility (log S) of a compound significantly affects its absorption and distribution characteristics.

The majority of the compounds identified have a low probability of being able to cross the BBB. In fact, only three compounds 12 have a good probability of being BBB permeates.

Pan-Assay Interference Compounds (PAINS) are very familiar to medicinal chemists who have spent time fruitlessly trying to optimize these nonprogressible compounds [54]. Table 4 shows that three of the compounds tested return a PAINS alert (15, 17, and 68).

The cytochrome P450 (CYP) superfamily is important in drug elimination through metabolic biotransformation. Inhibition of these isoenzymes is certainly a major cause of pharmacokinetic-related drug interactions leading to toxic or unwanted adverse effects due to the lower clearance and accumulation of the drug or its metabolites. Table 4 shows that all of compounds are found to be non-inhibitors of isoenzyme CYP1A2, except 12 and 66, and therefore the side effect (i.e., liver dysfunction) may be absent. CYP1A2 is expressed in the liver (10% of the total CYP content) and is responsible for the activation of aromatic and heterocyclic amines, PAHs, and many therapeutic drugs [55]. However, the compounds are predicted to be metabolized by CYP1A2, CYP2C19, CYP2C9, and CYP3A4 with more exceptions.

Skin permeability (log kp) is an important parameter for the evaluation of drugs, which may require transdermal administration [56]. The more negative the log Kp, the less skin permeant is the molecule. Except for compounds 40 and 48, the log Kp measurements of all the tested compounds are found to be within the limits (−10.0 to −1.0).

The toxicity prediction for the 7 compounds that did not violated Lipinski and Veber rules was based on different targets related to adverse drug reactions. The hepatotoxicity, carcinogenicity, mutagenicity, and cytotoxicity of the compounds have been determined [58]. Based on the results of ProTox II, it can be seen that the compound 66 is found to have mutagenicity. Compounds 12 and 62 are reported to be carcinogenicity. All compounds are not hepatotoxic and not cytotoxic (Table 5).

| Compound | Hepatotoxicity | Carcinogenicity | Mutagenicity | Cytotoxicity | LD50 (mg kg⁻¹) |
|----------|----------------|-----------------|--------------|--------------|----------------|
| 12       | Inactive       | Active          | Inactive     | Inactive     | 1000           |
| 15       | Inactive       | Inactive        | Inactive     | Inactive     | 340            |
| 17       | Inactive       | Inactive        | Inactive     | Inactive     | 2000           |
| 18       | Inactive       | Inactive        | Inactive     | Inactive     | 9000           |
| 41       | Inactive       | Inactive        | Inactive     | Inactive     | 500            |
| 62       | Inactive       | Active          | Inactive     | Inactive     | 2000           |
| 66       | Inactive       | Inactive        | Active       | Inactive     | 3850           |
Prediction of LD50 using ProTox II showed that compounds 12, 17, 18, 62, and 66 are predicted to have oral LD50 value ranging from 800 to 9000 mg kg\(^{-1}\) in rat model and have non-toxic effect predicted.

The results obtained from ADMET analysis reveal that compounds 17 and 18 are in good agreement with Lipinski’s and Veber’s rules with no violations; these two compounds have also acceptable ADMET properties. Compounds 17 and 18 could be orally administrated drug candidates. Moreover, compounds 17 and 18 were chosen to perform MD simulation study in order to investigate their stability on Mpro (6lu7) protein. The binding energy values observed for compounds 17 and 18 show that they possess good orientation shape with the active site of Mpro (6lu7) protein, through different interactions compared to chrysoeriol-7-O-β-D-glucuronopyranoside (BE = −8.0 kcal/mol) reported in our previous work [11].

**Molecular dynamics simulations**

The dynamic nature of the Mpro protein and their complexes were studied by simulating them in aqueous environment.
The RMSF of almost all residues of Mpro was obtained below 0.2 nm, showing the good stability of the protein. The presence of both ligands exhibited a negligible effect on the RMSF of Mpro. The analysis of RMSD and RMSF that confirmed the protein and the complexes was well stable under aqueous environment. The RMSF of all atoms of the ligands was also calculated as shown in Fig. 5. Compound 18 showed relatively more fluctuation, which means that compound 18 underwent more dynamical shift at the binding from than compound 17.

Assessment of Rg and SASA and energies

The mass-weighted root mean square distance of a collection of atoms from their common center of mass is defined as radius of gyration (R_g). This is also an important parameter to be considered while studying the stability of proteins in aqueous systems [59]. Generally, the compact and globular proteins exhibit less variation in their radius of gyration compared to the expanded form of protein [60]. The R_g of protein alone and their complexes are shown in Fig. 6.

As evident from the data, the R_g of Mpro remained constant during the entire simulation time. A similar observation was found for Mpro-compound_18 complex, while there was a slight variation in R_g of Mpro-compound_17 complex. These mean that all systems were stable during MD simulation. Moreover, the analysis of R_g also inducted that Mpro protein did not undergo major conformational changes [61].

Solvent accessible surface is another important parameter for staying the stability of proteins through MD simulation. The SASA of Mpro protein and their complexes are shown in Fig. 7.

SASA of all systems was found to be persistent over the entire trajectory of simulation. This further validates the stability of complexes.

Finally, the physicochemical parameters of all systems were also calculated. The total and potential energies of all systems were also calculated. The potential energy and total energy of Mpro, Mpro-compound_17 complex, and Mpro-compound_18 complex as a function of simulation time.
systems is presented in Fig. 8. Both these parameters were also found to be contact during simulation. The data finally validate the stability of all systems during MD simulation.

Assessment of the structural stability and hydrogen bonds

The effect of binding of both ligands in the structure stability of protein was studied by determining the secondary structural motifs of the proteins. Each secondary structure component of Mpro protein is shown in Fig. 9. The coils, β-sheet, β-bridge, bends, turns, and α-helix in Mpro were found to be 26.39, 25.99, 2.15, 7.20, 16.57, and 17.78%, respectively. All these secondary structures of Mpro change insignificantly when were complexed with compound 17 or compound 18. The data showed that the presence of ligands did not affect the structural stability of both the proteins.

The interaction between ligands and Mpro protein was studied by assessing the hydrogen bonds (Fig. 10). There was existence of H-bonds both in Mpro-compound_17 complex and Mpro-compound_18 complex throughout the entire simulation period. The average number of hydrogen bonds forming between Mpro and compound 18 was slightly more than that of compound 17. In all complexes, there was existence of H-bonds throughout the simulation period. However, there were slight variations in the H-bond profiles, which may be due to the dynamical shift of the ligands at the binding site.

Principal component analysis

Principal component analysis (PCA) is a standard statistical procedure to analyze the large-scale motion in biological macromolecules such as proteins and DNA. PCA is performed by reducing the dimensionality of data set without losing important information, which is characterized by eigenvectors [62]. PCA was done to explore the flexibility of Mpro protein and their complexes. The projection of eigenvectors in uncomplexed and complexed forms is presented in Fig. 11.

The data shows that Mpro alone and Mpro-compound_18 complex occupied a similar conformational space. However, Mpro-compound_17 complex occupied slightly

| Type of energy | Comp. 17 | Comp. 18 | N3       |
|----------------|---------|---------|----------|
| $\Delta E_{vdW}$ | $-30.46 \pm 0.32$ | $-42.53 \pm 0.38$ | $-173.639 \pm 2.083$ |
| $\Delta E_{ele}$ | $-10.13 \pm 0.23$ | $-7.27 \pm 0.34$ | $-41.902 \pm 1.424$ |
| $\Delta E_{PSE}$ | $29.61 \pm 0.36$ | $29.67 \pm 0.36$ | $170.300 \pm 3.244$ |
| $\Delta E_{SASA}$ | $-3.86 \pm 0.03$ | $-4.57 \pm 0.02$ | $-21.493 \pm 0.234$ |
| $\Delta E_{BE}$ | $-14.85 \pm 0.27$ | $-24.71 \pm 0.39$ | $-66.745 \pm 2.640$ |

$\Delta E_{vdW}$ van der Waal energy, $\Delta E_{ele}$ electrostatic energy, $\Delta E_{PSE}$ polar solvation energy, $\Delta E_{SASA}$ solvent accessible surface area energy, $\Delta E_{BE}$ binding energy.

![Fig. 12](image1)

Free energy landscape plot of (A) Mpro, (B) Mpro-compound_17 complex, and (C) Mpro-compound_18 complex

![Fig. 13](image2)

Ramachandran plot of the energy minima of BSA in the absence and presence of BR
more conformational space. This shows that the Mpro-
compound_17 exhibited slightly more structural flexibility
compared to Mpro alone and Mpro-compound_18 complex.

The free energy landscapes (FEL) of Mpro protein and
complexes were also plotted to explore the variations in the
patterns of protein folding (Fig. 12). The FEL shows that
all systems reached energy minima in their respective land-
scapes. The lowest energy minima structures of the proteins
were extracted to plot the respective Ramachandran plots.
The Ramachandran plots of the protein and their complexes
showed that almost all amino acids were found the favorable
region (Fig. 13).

**MM-PBSA calculation**

The detailed insight regarding various binding energies
involved for the interaction of both ligands with Mpro pro-
tein as done using MM-PBSA calculations. Non-covalent
forces mainly stabilize the protein ligand interactions mostly,
which include electrostatic, hydrophobic interactions,
hydrogen bonds, and Van Der Waals force. These forces
may either contribute positively or negatively to the overall
binding [63].

For MM-PBSA calculations, 100 frames were extracted
from 60 to 100 ns from the trajectory of each complex. The
MM-PBSA binding energies are enlisted in Table 6.

The van Der Waals energy was found to be the major
contributor in overall binding energy followed by the electro-
static energy. Moreover, there was also small contribution of
SASA energy. However, polar solvation energy impaired the
binding of both ligands to Mpro protein. The overall bind-
ing energy for interaction of compound 17 and compound
18 to Mpro was found to be $-14.85$ and $-24.71 \text{ kcal mol}^{-1}$,
respectively. It is interesting to note that the MM-PBSA
binding energy of compounds 17 and 18 with the Mpro pro-
tein (6lu7) was more compared to the respective controls.
This shows the stronger binding affinity of compounds 17
and 18 compared to the control N3 for 6lu7.

The MM-PBSA data was further used to identify the key
residues, which gave maximum contribution in the binding
(Table 7). For interaction of compound 17 with Mpro, Thr25,
Leu27, Val42, Ile43, Thr45, Ser46, Met49, Arg60, Lys61,
Leu141, Gly143, Cys145, His164, and Glu166 were the major
energy contributors. Thr25, Leu27, Val42, Met49, Leu141,
Cys145, Met165, Glu166, Asp187, and Gln189 were the key
energy contributors for compound 18 Mpro interaction.

**Conclusion**

Despite the huge effort made to control the current pan-
demic, the COVID-19 disease continues spreading through-
out the globe. Nowadays, many vaccines are developed and
are approved for emergency use even though most people of
the world are not vaccinated yet, in particular, people belong-
ing to developing country. It seems that the development of
antiviral drugs could be a good strategy to fight against this
continued pandemic. For this context, we have performed
this in silico study, which aims to develop an inhibitor of
both Mpro (6lu7) SARS-CoV-2 protein. The study was con-
ducted on 84 molecules collected from four medicinal plants
belonging to Cameroonian flora. Among the 84 compounds,
only 15 compounds have shown good binding affinity in
the molecular docking analysis compared to the reference

| Residues | Compound 17 E_polar | E_Apolar | E_total | Residues | Compound 18 E_polar | E_Apolar | E_total |
|----------|---------------------|----------|---------|----------|---------------------|----------|---------|
| Thr-25   | 2.786               | -0.274   | -1.240  | Thr-25   | 0.154               | -0.092   | -0.643  |
| Leu-27   | 0.150               | -0.036   | -0.700  | Leu-27   | 0.087               | -0.067   | -0.718  |
| Val-42   | 0.289               | -0.001   | -0.110  | Val-42   | 0.064               | -0.000   | -0.200  |
| Ile-43   | -0.185              | -0.000   | -0.176  | Met-49   | 0.520               | -0.251   | -1.717  |
| Thr-45   | 2.120               | -0.086   | -0.341  | Leu-141  | 0.106               | -0.014   | -0.324  |
| Ser-46   | 1.827               | -0.203   | -0.159  | Cys-145  | 0.786               | -0.123   | -0.834  |
| Met-49   | 0.349               | -0.123   | -0.658  | Met-165  | 1.093               | -0.202   | -1.689  |
| Arg-60   | 0.030               | -0.000   | -0.179  | Glu-166  | 1.166               | -0.093   | -0.257  |
| Lys-61   | -0.030              | -0.000   | -0.445  | Asp-187  | 0.946               | -0.045   | -0.476  |
| Leu-141  | -0.042              | 0.000    | -0.106  | Gln-189  | 1.114               | -0.159   | -0.534  |
| Gly-143  | 0.609               | -0.104   | -0.338  |          |                     |          |         |
| Cys-145  | 0.216               | -0.044   | -0.345  |          |                     |          |         |
| His-164  | 0.090               | -0.000   | -0.1201 |          |                     |          |         |
| Glu-166  | -0.158              | -0.001   | -0.422  |          |                     |          |         |

$E_{\text{polar}}$ polar energy, $E_{\text{Apolar}}$ apolar energy, $E_{\text{total}}$ total energy
The binding energies of the 15 compounds were in the range of −7.8 kcal/mol and −8.5 kcal/mol, which are near to that obtained for Nelfinavir (−8.2 kcal/mol). The selected 15 compounds were subjected to ADMET analysis to evaluate their absorption, distribution, metabolism, and toxicity properties. The results have shown that compounds 17 and 18 obtained from *Pycnanthus angolensis* are strongly recommended to be potential drugs against COVID-19. Further analysis was performed using molecular dynamics (MD) simulation to ensure the stability of compounds 17 and 18 on the 6u7 protein. The obtained results have shown good stability for both compounds on the active sites of the protein during the simulation period. Relying on the results obtained from this study and in the light of previously described works, Pycnanthuquinone C (17) and Pycnanthuquinone B (18) could be considered as in silico inhibitors against M^\text{NSP}^\text{SARS-CoV-2} protein. Experimental investigations should be carried out to assess their in vitro and in vivo efficiency against SARS-CoV-2.

### Supplementary information
The online version contains supplementary material available at [https://doi.org/10.1007/s11224-022-01939-7](https://doi.org/10.1007/s11224-022-01939-7).

### Author contribution
Samir Chitta: writing, original draft preparation, conceptualization, methodology, software, and supervision; Romuald Tematio Foudenjou: data curation, writing, and original draft preparation; Loris Alvine Djoumbissie, Mohammed Bakhouk, and Mohammed Efendi: visualization and original draft preparation; Mebarka Ouassaf and Faizan Abul Qais: conceptualization, writing, and original draft preparation; Salah Belaidi, Tugba Taskin Tok, Mohammed Bouachrine, and Tahar Lakhifli: visualization and validation.

### Data availability
All data used in this work are private.

### Code availability
The codes used in this work are not available.

### Declarations

#### Conflict of interest
The authors declare no competing interests.

### References

1. Fatima E, Ben AF, Dahmani J, Belahbib N, Zidane L (2015) Étude ethnombotanique des plantes médicinales utilisées dans le traitement des infections du système respiratoire dans le plateau central marocain. J Anim Plant Sci 25:3886–3897
2. Fuhrman C, Delmas M-C (2010) Épidémiologie descriptive de la bronchopneumopathie chronique obstructive (BPCO) en France. Rev Mal Respir 27(2):160–168. [https://doi.org/10.1016/j.rmr.2009.08.003](https://doi.org/10.1016/j.rmr.2009.08.003)
3. Adjohounou E (2000) La biodiversité face au développement des industries pharmaceutiques africaines. In Réseau des espèces ligneuses médicinales, Eyog Matig O, Adjohounou E, de Souza S and Sinisn B (eds), Comptes rendus de la première réunion du réseau tenu 15–17 décembre 1999 à la station IITA Cotonou, Bénin, 88–103
4. Dibong SD, Mpondo ME, Ngoy A, Kwin NF (2011) Plantes médicinales utilisées par les populations bassa de la région de Douala au Cameroun. Int J Biol Chem Sci 5:1105–1117
5. Koné D (2009) Enquête ethnombotanique de six plantes médicales maliennes - extraction, identification d’alcaloïdes - caractérisation, quantification de polyphénols: étude de leur activité antioxydante. Thèse de Doctorat Université de Bamako, Mali, 157
6. Benlamdini N, Elhabia M, Roched A, Zidane L (2014) Étude floristique et ethnombotanique de la flore médicinale du Haut Atlas oriental (Haute Moulouya). J Appl Biosci 78:6767–6787
7. Foudenjou TR, Teponto RB, Quassinti L, Bramucci M, Petrelli D, Vitali AL, Fiorini D, Tandonjou AL, Barboni L (2014) Steroidal saponins from the leaves of Cordyline fruticosa L. A. Chev. and their cytotoxic and antimicrobial activity. Phytochemistry Lett 7:62–68
8. Foudenjou TR, Nguelefack-Mbuoy PE, Ponou KB, Nguelefack BT, Barboni L, Toundjou AL (2016) Antioxidant activities and chemical constituents of extracts from Cordyline fruticosa (Agavaceae) and Eriobotrya japonica (Rosaceae). Pharmacologia 7(103):113–120
9. WHO World Health Organization (2021). [https://covid19.who.int/](https://covid19.who.int/)
10. Biyiti LF, Mek'o'o DJL, Tamze V, Amvam Zollo PH (2004) Recherche de l’activité antibactérienne de quatre plantes médicales camerounaises. Pharm Med Trad Afr 13:11–20
11. Foudenjou RT, Chitta S, Bakhouch M, Belaidi S, Ouassaf M, Djoumbissie LA, Toundjou LA, Abul Qais F (2021) Cameroonian medicinal plants as potential candidates of SARS-CoV-2 inhibitors. J Biomol Struct Dyn 1–15. [https://doi.org/10.1080/07391102.2021.1914710](https://doi.org/10.1080/07391102.2021.1914710)
12. Fort DM, Ubillas RP, Mendez CD, Jolad SD, Inman WD, Carney JR, Chen JL, Ianiro TT, Hasbun C, Bruening RC, Luo J (2000) Novel antihyperglycemic terpenoid-quinones from *Pycnanthus angolensis*, J Org Chem 65:6534–6539. [https://doi.org/10.1021/jo000568q](https://doi.org/10.1021/jo000568q)
13. Wabo H, Tatsimo S, Tane P, Connolly J (2007) Pycnanthuquinone C: a new terpenoid-quinone from *Pycnanthus angolensis*. Planta Med 73:187–189. [https://doi.org/10.1055/s-2007-967103](https://doi.org/10.1055/s-2007-967103)
14. Abrantes M, Mil-Homens T, Duarte N, Lopes D, Cravo P, Madureira M, Ferreira M-J (2008) Antiplasmodial activity of lignonans and extracts from *Pycnanthus angolensis*. Planta Med 74:1408–1412. [https://doi.org/10.1055/s-2008-1081317](https://doi.org/10.1055/s-2008-1081317)
15. Onono ECN, Mkounja P, Kute V, Marat K, Hultin PG, Nkengfack AE (2010) Pycnanthuigenes A–D, antimicrobial cyclolignane derivatives from the roots of *Pycnanthus angolensis*. J Nat Prod 73:213–216. [https://doi.org/10.1021/np9007393](https://doi.org/10.1021/np9007393)
16. Tsaassi VB, Hussain H, Tamboue H, Dongo E, Kouam SF, Krohn K (2010) Pycnangloside: a new cerebroside from bark of *Pycnanthus angolensis*, Nat Prod Commun 5(11):1934587X1000501. [https://doi.org/10.1177/1934578X100051121](https://doi.org/10.1177/1934578X100051121)
17. Abourashed EA, Toyang NJ, Choisinski J, Khan IA (1999) Two new flavone glycosides from Paullinia pinnata. J Nat Prod 62:1179–1181. [https://doi.org/10.1021/np990063z](https://doi.org/10.1021/np990063z)
18. Miemanang RS, Krohn K, Hussain H, Dongo E (2007) Paullinoside A and paullinomide A: a new cerebroside and a new ceramide from leaves of *Paullinia pinnata*. ChemInform 38. [https://doi.org/10.1002/chin.200703188](https://doi.org/10.1002/chin.20070318)
19. Annan K, Houghton PJ (2010) Two novel lupane triterpenoids from *Paullinia pinnata* L. with fibroblast stimulatory activity. J Pharm Pharmacol 62:663–668. [https://doi.org/10.1211/jpp.62.05.0016](https://doi.org/10.1211/jpp.62.05.0016)
20. Lasissi AA, Ayinde BW, Adeleye AO, Onocha PA, Oloadosu IA, Idowu PA (2015) New triterpene isovanniloyl and antibacterial activity of constituents from the roots of *Paullinia pinnata* Linn (Sapindaceae). J Saudi Chem Soc 19:117–122. [https://doi.org/10.1016/j.jscs.2011.12.012](https://doi.org/10.1016/j.jscs.2011.12.012)
21. Jackson N, Annan K, Mensah AY, Ekuadzi E, Mensah MLK, Hubtemariam S (2015) A novel triterpene from the roots of *Paulinia pinnata*: 6α-(3′-methoxy-4′-hydroxybenzoyl)-lup-20(29)-ene-3-one. Nat Prod Commun 10:1934578X1501000405. [https://doi.org/10.1177/1934578X1501000405](https://doi.org/10.1177/1934578X1501000405)
22. Lunga P-K, Qin X-J, Yang X-W, Kuiate J-R, Du Z-Z, Gatsing D (2015) A new antimicrobial and radical-scavenging glycoside from Paulinia pinnata var. cameroonensis. Nat Prod Res 29:1688–1694. https://doi.org/10.1080/14786419.2014.996756

23. Lunga PK, Qin X-J, Yang XW, Kuiate J-R, Du ZZ, Gatsing D (2014) Antimicrobial steroidal saponin and oleanane-type triterpenoid saponins from Paulinia pinnata. BMC Complement Altern Med 14:369. https://doi.org/10.1186/1472-6882-14-369

24. Miemanang RS, Krohn K, Hussain H, Dongo E (2014) Paulinoside A and paulinoamide A: a new cerebroside and a new ceramides from leaves of Paulinia pinnata. Zeitschrift für Naturforschung B 69(9):1123–1127. https://doi.org/10.1515/znb-2006-0910

25. Awouafack MD, Ito T, Tane P, Kodama T, Tanaka M, Asakawa Y, Morita H (2016) A new cycloartane-type triterpenoid and a new eicosanoic acid ester from fruits of Paulinia pinnata. L Phytochem Lett 15:220–224. https://doi.org/10.1016/j.phytol.2016.02.002

26. Nkengfack AE, Azebaze GA, Vandamiades JC, Fonoum ZT, van Heerden FR (2002) A prenylated xanthone from Allanblackia floribunda. J Ethnopharmacol 81:399–401. https://doi.org/10.1016/S0378-8741(02)00036-5

27. Kuete V, Azebaze AGB, Mbaveng ArmelleT, Nguemo EL, Tshikalange ET, Chalard P, Nkengfack AE (2011) Antioxidant, antimicrobial and antiviral activities of the crude extract and compounds of the root bark of Allanblackia floribunda. Pharm Biol 49:57–65. https://doi.org/10.3109/13880209.2010.494673

28. Akpanika GA, Winters T, Ayoola GA, Adepoju-Bello AA, Hauck B (2017) Polyphenols from Allanblackia floribunda: identification, quantification and antioxidant activity. Food Chem 222:35–42. https://doi.org/10.1016/j.foodchem.2016.12.002

29. Mountessou BYG, Tchamgoue J, Paul Dzoyem J, Tchuengoue RT, Surup F, Choudhary MI, Green IR, Kouam SF (2018) Two xanthones and two rotameric (3→8) biflavonoids from the Cameroonian medicinal plant Allanblackia floribunda Oliv. (Guttiferae). Tetrahedron Lett 59:4545–4550. https://doi.org/10.1016/j.tetlett.2018.11.035

30. Banzouzi J-T, Prado R, Menan H, Valentin A, Roumenst C, Mallie M, Pelissier Y, Blache Y (2002) In vitro antiplasmodial activity of extracts of Alchornea cordifolia and identification of an active constituent: ellagic acid. J Ethnopharmacol 81:399–401. https://doi.org/10.1016/S0378-8741(02)00036-5

31. Van Der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, Berendsen HJC (2005) GROMACS: fast, flexible, and free. J Comput Chem 26(16):1701–1718. https://doi.org/10.1002/jcc.20291

32. Maier JA, Martinez C, Kasavajhala K, Wickstrom L, Hauser KE, Berendsen HJC (2004) Use of nelfinavir stereoisomers on coronavirus main protease: molecular docking, molecular dynamics and ADMET evaluation. J Biomol Struct Dyn 21:7182–7190. https://doi.org/10.1080/07391102.2020.1779130

33. Piarulli M, Rahman A (1981) Polymorphic transitions in single crystals: a new molecular dynamics method. J Appl Phys 52(12):7182–7190. https://doi.org/10.1063/1.328693

34. Bussi G, Donadio D, Parrinello M (2007) Canonical sampling through velocity rescaling. J Chem Phys 126(1):014101. https://doi.org/10.1063/1.2408420

35. Parrinello M, Rahman A (2007) Antismooth transitions in single crystals: a new molecular dynamics method. J Appl Phys 52(12):7182–7190. https://doi.org/10.1063/1.328693

36. Kumari R, Kumar R, Lynn A (2014) G_mmpbsa - a GROMACS tool for high-throughput MM-PBSA calculations. J Chem Inf Model 54(7):1951–1962. https://doi.org/10.1021/ci500020m

37. Sargsyan A, Azebaze AE, Belaidi S, Bouachrine M, Lahlifi T (2021) Discovery of potent SARS-CoV-2 inhibitors from approved antiviral drugs via docking screening, combinatorial chemistry & high throughput screening 24(3):441–454. https://doi.org/10.2174/138620732399920020730205447. https://doi.org/10.1093/glycob/1.6.631
52. Bickerton GR, Paolini GV, Besnard J, Muresan S, Hopkins AL (2012) Quantifying the chemical beauty of drugs. Nat Chem 4(2):90–98. https://doi.org/10.1038/nchem.1243

53. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD (2002) Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 45:2615–2623. https://doi.org/10.1021/jm020017n

54. Baell JB, Nissink WM (2018) Seven year itch: pan-assay interference compounds (PAINS) in 2017—utility and limitations. ACS Chem Biol 13(1):36–44. https://doi.org/10.1021/acscmbio.7b00903

55. Di L (2014) The role of drug metabolizing enzymes in clearance. Expert Opin Drug Metab Toxicol 10:379–393. https://doi.org/10.1517/17425255.2014.876006

56. Singh S, Singh J (1993) Transdermal drug delivery by passive diffusion and iontophoresis: a review. Med Res Rev 13(5):569–621. https://doi.org/10.1002/med.2610130504

57. Imberty A, Hardman KD, Carver JP, Perez S (1991) Molecular modelling of protein-carbohydrate interactions. docking of monosaccharides in the binding site of concanavalin A. Glycobiology 1(6):631–642

58. Loukine E, Keiser MJ, Whitebread S, Mikhailov D, Hamon J, Jenkins JL, Lavan P, Weber E, Doak AK, Côté S, Shoichet BK, Urban L (2012) Large-scale prediction and testing of drug activity on side-effect targets. Nature 486(7403):361–367. https://doi.org/10.1038/nature11159

59. Qais FA, Sarwar T, Ahmad I, Khan RA, Shahzad SA, Husain FM (2021) Glyburide inhibits non-enzymatic glycation of HSA: an approach for the management of AGEs associated diabetic complications. Int J Biol Macromol 169:143–152. https://doi.org/10.1016/j.ijbiomac.2020.12.096

60. Foudjou TR, Chitita S, Bakhouch M, Belaidi S, Ouassa M, Djoumbissie AL, Tapondjou AL (2021) Cameroon medicinal plants as potential candidates of SARS CoV-2 inhibitors. J Biomol Struct Dyn 39:1–16

61. Rath B, Qais FA, Patro R, Mohapatra S, Sharma T (2021) Design, synthesis and molecular modeling studies of novel mesalamine linked coumarin for treatment of inflammatory bowel disease. Bioorg Med Chem Lett 128029. https://doi.org/10.1016/j.bmcl.2021.128029

62. Siddiqui S, Ameen F, Kausar T, Nayeem SM, Ur Rehman S, Tabish M (2021) Biophysical insight into the binding mechanism of doxofylline to bovine serum albumin: an in vitro and in silico approach. Spectrochim Acta Part A Mol Biomol Spectrosc 249:119296. https://doi.org/10.1016/j.saa.2020.119296

63. Siddiqui S, Ameen F, Jahan I, Nayeem SM, Tabish M (2019) A comprehensive spectroscopic and computational investigation on the binding of the anti-asthmatic drug triamcinolone with serum albumin. New J Chem 43(10):4137–4151. https://doi.org/10.1039/C8NJ05486J

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.